SG Americas Securities LLC Acquires New Position in ImmunityBio, Inc. (NASDAQ:IBRX)

SG Americas Securities LLC acquired a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 59,775 shares of the company’s stock, valued at approximately $222,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of IBRX. Bleakley Financial Group LLC purchased a new position in shares of ImmunityBio in the 1st quarter valued at approximately $58,000. Lazard Asset Management LLC raised its position in shares of ImmunityBio by 102.6% in the 1st quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock valued at $68,000 after purchasing an additional 6,593 shares during the last quarter. Axxcess Wealth Management LLC purchased a new position in shares of ImmunityBio in the 1st quarter valued at approximately $85,000. Algert Global LLC purchased a new position in shares of ImmunityBio in the 2nd quarter valued at approximately $86,000. Finally, Brookstone Capital Management purchased a new position in shares of ImmunityBio in the 1st quarter valued at approximately $100,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Trading Down 1.7 %

Shares of NASDAQ:IBRX opened at $3.49 on Wednesday. The company has a market cap of $2.41 billion, a PE ratio of -3.20 and a beta of 1.02. ImmunityBio, Inc. has a twelve month low of $1.28 and a twelve month high of $10.53. The company’s 50 day moving average is $3.70 and its 200 day moving average is $5.39.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $2.53 million. Equities research analysts predict that ImmunityBio, Inc. will post -0.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Piper Sandler cut their price target on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a report on Monday, August 19th.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.